Hydroxyurea-Increased Fetal Hemoglobin Is Associated with Less Organ Damage and Longer Survival in Adults with Sickle Cell Anemia
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Adults with sickle cell anemia (HbSS) are inconsistently treated with hydroxyurea. OBJECTIVES: We retrospectively evaluated the effects of elevating fetal hemoglobin with hydroxyurea on organ damage and survival in patients enrolled in our screening study between 2001 and 2010. METHODS: An electronic medical record facilitated development of a database for comparison of study parameters based on hydroxyurea exposure and dose. This study is registered with ClinicalTrials.gov, number NCT00011648. RESULTS: Three hundred eighty-three adults with homozygous sickle cell disease were analyzed with 59 deaths during study follow-up. Cox regression analysis revealed deceased subjects had more hepatic dysfunction (elevated alkaline phosphatase, Hazard Ratio = 1.005, 95% CI 1.003-1.006, p<0.0.0001), kidney dysfunction (elevated creatinine, Hazard Ratio = 1.13, 95% CI 1.00-1.27, p = 0.043), and cardiopulmonary dysfunction (elevated tricuspid jet velocity on echocardiogram, Hazard Ratio = 2.22, 1.23-4.02, p = 0.0082). Sixty-six percent of subjects were treated with hydroxyurea, although only 66% of those received a dose within the recommended therapeutic range. Hydroxyurea use was associated with improved survival (Hazard Ratio = 0.58, 95% CI 0.34-0.97, p = 0.040). This effect was most pronounced in those taking the recommended dose of 15-35 mg/kg/day (Hazard Ratio 0.36, 95% CI 0.17-0.73, p = 0.0050). Hydroxyurea use was not associated with changes in organ function over time. Further, subjects with higher fetal hemoglobin responses to hydroxyurea were more likely to survive (p = 0.0004). While alkaline phosphatase was lowest in patients with the best fetal hemoglobin response (95.4 versus 123.6, p = 0.0065 and 96.1 versus 113.6U/L, p = 0.041 at first and last visits, respectively), other markers of organ damage were not consistently improved over time in patients with the highest fetal hemoglobin levels. CONCLUSIONS: Our data suggest that adults should be treated with the maximum tolerated hydroxyurea dose, ideally before organ damage occurs. Prospective studies are indicated to validate these findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increased HbF associated with taking 15 to 35 mg/kg hydroxyurea improved survival in 393 HbS homozygotes (HR: 0.36; 95% CI: 0.17-0.73).62”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [62]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mortality in sickle cell disease. Life expectancy and risk factors for early death
Platt, O. S., Brambilla, D. J., Rosse, W. F., Milner, P. F., Castro, O., Steinberg, M. H., & Klug, P. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406093302303 · Cited by 3,320 · cited 5×
“It is possible that HbF approaching 30% may be crucial to prevent organ injury and vascular damage [2].”
BackgroundResultInfluentialEffect of hydroxyurea on the frequency of painful crises in sickle cell anemia
Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B., Eckert, S. V., McMahon, R. P., & Bonds, D. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322001 · Cited by 2,340 · cited 2×
“0001 at last visit in subjects taking versus not taking hydroxyurea), the value was considerably above the ANC of 2,000u/L which defines the maximum tolerated dose [10].”
BackgroundPulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease
Gladwin, M. T., Sachdev, V., Jison, M. L., Shizukuda, Y., Plehn, J. F., Minter, K., Brown, B., Coles, W. A., Nichols, J. S., Ernst, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035477 · Cited by 1,325
Self-citationPathogenesis and Treatment of Sickle Cell Disease
Bunn, H. F. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709113371107 · Cited by 1,154 · cited 1×
“Homozygous sickle cell disease (HbSS) leads to polymerization of deoxygenated sickle hemoglobin within rigid red blood cells (RBC) which then occlude microvasculature, resulting in acute complications, chronic organ damage, and premature death [1].”
BackgroundWang, W. C., Ware, R. E., Miller, S. T., Iyer, R. V., Casella, J. F., Minniti, C. P., Rana, S., Thornburg, C. D., Rogers, Z. R., Kalpatthi, R. V., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60355-3 · Cited by 803 · cited 1×
“A randomized study of fixed dose hydroxyurea (20 mg/kg/day versus placebo) in infants with HbSS showed improvement in markers of splenic function, suggesting that even modest HbF increases can be beneficial [28].”
BackgroundSelf-citationOutcome of Sickle Cell Anemia: A 4-Decade Observational Study of 1056 Patients
Powars, D. R., Chan, L. S., Hiti, A., Ramicone, E., & Johnson, C. (2005) · Medicine · doi:10.1097/01.md.0000189089.45003.52 · Cited by 558 · cited 1×
“This contrasts a four decade observational study, where most deaths were associated with irreversible end organ damage [3].”
BackgroundHydroxyurea enhances fetal hemoglobin production in sickle cell anemia.
Platt, O. S., Orkin, S. H., Dover, G., Beardsley, G. P., Miller, B., & Nathan, D. G. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111464 · Cited by 535 · cited 1×
“The MSH did not specifically report fetal hemoglobin (HbF) responses, although other reports have shown that hydroxyurea largely exerts its effect by increasing HbF and inhibiting RBC sickling [11,12].”
BackgroundThe risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up
Steinberg, M. H., McCarthy, W. F., Castro, O., Ballas, S. K., Armstrong, F. D., Smith, W., Ataga, K., Swerdlow, P., Kutlar, A., DeCastro, L., et al. (2010) · American Journal of Hematology · doi:10.1002/ajh.21699 · Cited by 486 · cited 3×
“Long-term hydroxyurea studies suggest improved survival [7,8,14].”
Voskaridou, E., Christoulas, D., Bilalis, A., Plata, E., Varvagiannis, K., Stamatopoulos, G., Sinopoulou, K., Balassopoulou, A., Loukopoulos, D., & Terpos, E. (2010) · Blood · doi:10.1182/blood-2009-05-221333 · Cited by 430 · cited 4×
“First, laboratory studies indicating a more severe phenotype, including lower HbF and higher WBC and LDH values, were significantly different prior to death compared to those still living [2,8].”
BackgroundResultInfluentialMortality Rates and Age at Death from Sickle Cell Disease: U.S., 1979–2005
Lanzkron, S., Carroll, C. P., & Haywood, C. (2013) · Public Health Reports® · doi:10.1177/003335491312800206 · Cited by 414 · cited 1×
“Health database studies have shown no change in mortality since hydroxyurea approval [9,17], and recent studies have shown no association between current hydroxyurea use and mortality [16,18,19].”
BackgroundFetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea
Steinberg, M. H., Lu, Z.-H., Barton, F. B., Terrin, M. L., Charache, S., Dover, G. J., & Hydroxyurea, T. M. S. O. (1997) · Blood · doi:10.1182/blood.v89.3.1078 · Cited by 407
How I use hydroxyurea to treat young patients with sickle cell anemia
Ware, R. E. (2010) · Blood · doi:10.1182/blood-2009-04-146852 · Cited by 396 · cited 1×
“The insufficiently suppressed ANC and a lack of hemoglobin rise suggest that hydroxyurea dosing could be increased to a maximally tolerated dose as is frequently recommended by pediatric hematologists in the United States [27].”
BackgroundIs there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia?
Powars, D., Weiss, J., Chan, L., & Schroeder, W. (1984) · Blood · doi:10.1182/blood.v63.4.921.921 · Cited by 314
Factors associated with survival in a contemporary adult sickle cell disease cohort
Elmariah, H., Garrett, M. E., De Castro, L. M., Jonassaint, J. C., Ataga, K. I., Eckman, J. R., Ashley‐Koch, A. E., & Telen, M. J. (2014) · American Journal of Hematology · doi:10.1002/ajh.23683 · Cited by 300 · cited 2×
“Recent studies reported no survival difference based on hydroxyurea use [16,18]; however, dosing was not mentioned.”
BackgroundHematologic Responses of Patients with Sickle Cell Disease to Treatment with Hydroxyurea
Rodgers, G. P., Dover, G. J., Noguchi, C. T., Schechter, A. N., & Nienhuis, A. W. (1990) · New England Journal of Medicine · doi:10.1056/nejm199004123221504 · Cited by 278 · cited 1×
“The MSH did not specifically report fetal hemoglobin (HbF) responses, although other reports have shown that hydroxyurea largely exerts its effect by increasing HbF and inhibiting RBC sickling [11,12].”
BackgroundSelf-citationCircumstances of death in adult sickle cell disease patients
Darbari, D. S., Kple-Faget, P., Kwagyan, J., Rana, S., Gordeuk, V. R., & Castro, O. (2006) · American Journal of Hematology · doi:10.1002/ajh.20685 · Cited by 276
Cardiopulmonary complications leading to premature deaths in adult patients with sickle cell disease
Fitzhugh, C. D., Lauder, N., Jonassaint, J. C., Telen, M. J., Zhao, X., Wright, E. C., Gilliam, F. R., & De Castro, L. M. (2010) · American Journal of Hematology · doi:10.1002/ajh.21569 · Cited by 224
Self-citationTaylor, J. G., Nolan, V. G., Mendelsohn, L., Kato, G. J., Gladwin, M. T., & Steinberg, M. H. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002095 · Cited by 184 · cited 1×
“Hemoglobin was not different between groups, suggesting that these parameters might reflect chronic tissue damage and not increased hemolysis [23].”
BackgroundSelf-citationThe effect of hydroxcarbamide therapy on survival of children with sickle cell disease
Lopes de Castro Lobo, C., Pinto, J. F. C., Nascimento, E. M., Moura, P. G., Cardoso, G. P., & Hankins, J. S. (2013) · British Journal of Haematology · doi:10.1111/bjh.12323 · Cited by 161 · cited 2×
“Long-term hydroxyurea studies suggest improved survival [7,8,14].”
BackgroundDarbari, D. S., Wang, Z., Kwak, M., Hildesheim, M. E., Nichols, J., Allen, D. T., Seamon, C. A., Peters-Lawrence, M. H., Conrey, A. K., Hall, M. K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079923 · Cited by 138 · cited 2×
“Health database studies have shown no change in mortality since hydroxyurea approval [9,17], and recent studies have shown no association between current hydroxyurea use and mortality [16,18,19].”
BackgroundSelf-citationGladwin, M. T., Barst, R. J., Gibbs, J. S. R., Hildesheim, M., Sachdev, V., Nouraie, M., Hassell, K. L., Little, J. A., Schraufnagel, D. E., Krishnamurti, L., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099489 · Cited by 132 · cited 2×
“Recent studies reported no survival difference based on hydroxyurea use [16,18]; however, dosing was not mentioned.”
BackgroundSelf-citationLanzkron, S., Rand, C. S., Haywood, C., & Hassell, K. L. (2008) · Journal of the National Medical Association · doi:10.1016/s0027-9684(15)31420-6 · Cited by 102 · cited 1×
“This is an improvement over prior reports where less than 50% of clinicians and only 16% of hematologists prescribed hydroxyurea [24,25].”
ResultPatterns of mortality in sickle cell disease in adults in France and England
Perronne, V., Roberts-Harewood, M., Bachir, D., Roudot‐Thoraval, F., Delord, J.-M., Thuret, I., Schaeffer, A., Davies, S. C., Galactéros, F., & Godeau, B. (2002) · The Hematology Journal · doi:10.1038/sj.thj.6200147 · Cited by 102
Mortality in sickle cell patients on hydroxyurea therapy
Bakanay, S. M., Dainer, E., Clair, B., Adekile, A., Daitch, L., Wells, L., Holley, L., Smith, D., & Kutlar, A. (2005) · Blood · doi:10.1182/blood-2004-01-0322 · Cited by 100 · cited 1×
“Because organ dysfunction may limit dosing [15] and hydroxyurea may not reverse severe tissue injury, we recommend treatment before organ damage occurs [7].”
BackgroundHankins, J. S., Helton, K. J., McCarville, M. B., Li, C., Wang, W. C., & Ware, R. E. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21271 · Cited by 99 · cited 1×
“Conversely, two pediatric studies where patients were treated with maximally tolerated doses of hydroxyurea reported splenic regeneration [29,30]; one confirming that 25% HbF was more likely to be associated with some splenic regeneration as compared to 14% HbF [30].”
ResultZumberg, M. S., Reddy, S., Boyette, R. L., Schwartz, R. J., Konrad, T. R., & Lottenberg, R. (2005) · American Journal of Hematology · doi:10.1002/ajh.20353 · Cited by 79 · cited 1×
“This is an improvement over prior reports where less than 50% of clinicians and only 16% of hematologists prescribed hydroxyurea [24,25].”
ResultEstepp, J. H., Smeltzer, M. P., Wang, W. C., Hoehn, M. E., Hankins, J. S., & Aygün, B. (2013) · British Journal of Haematology · doi:10.1111/bjh.12238 · Cited by 61
Taylor, J. G., Ackah, D., Cobb, C., Orr, N., Percy, M. J., Sachdev, V., Machado, R., Castro, O., Kato, G. J., Chanock, S. J., et al. (2008) · American Journal of Hematology · doi:10.1002/ajh.21035 · Cited by 60 · cited 1×
“Sickle cell disease (SCD) phenotypes were assigned based upon DNA sequencing and/or high performance liquid chromatography [21].”
MethodSelf-citationNottage, K. A., Ware, R. E., Winter, B., Smeltzer, M. P., Wang, W. C., Hankins, J. S., Dertinger, S. D., Shulkin, B. L., & Aygün, B. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12361 · Cited by 42
Randomized Clinical Trials and Observational Studies Are More Often Alike Than Unlike
Ross, J. S. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.3366 · Cited by 42 · cited 1×
“However, because SCD is an orphan disease, this study provides real world data with conclusions overlapping with prospective trials [32].”
ResultSickle Cell Disease Patients in U.S. Hospitals, 2004: Statistical Brief #21
Steiner, C., & Miller, J. L. (2006) · Agency for Healthcare Research and Quality (US), Rockville (MD) eBooks · Cited by 20
Research works printed but not linked: 1
- K Nottage, 2013, Hydroxyurea Preserves Splenic Function Among Children with Sickle Cell Anemia, Pediatric Blood and Cancer, 60, S24
Cited by
Piel, F. B., Rees, D. C., DeBaun, M. R., Nnodu, O., Ranque, B., Thompson, A. A., Ware, R. E., Abboud, M. R., Abraham, A., Ambrose, E. E., et al. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(23)00096-0 · Cited by 177
Fetal hemoglobin in sickle cell anemia
Steinberg, M. H. (2020) · Blood · doi:10.1182/blood.2020007645 · Cited by 136
Fitzhugh, C. D., Hsieh, M. M., Taylor, T., Coles, W., Roskom, K., Wilson, D., Wright, E., Jeffries, N., Gamper, C. J., Powell, J., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2016002972 · Cited by 105
“The majority of patients experience a poor quality of life and significantly reduced lifespan.(1,2,4) The most readily available curative option remains allogeneic hematopoietic stem cell transplantation (HSCT).”
BackgroundSelf-citationPecker, L. H., & Lanzkron, S. (2021) · Annals of Internal Medicine · doi:10.7326/aitc202101190 · Cited by 112
Qureshi, A., Kaya, B., Pancham, S., Keenan, R., Anderson, J., Akanni, M., Howard, J., & the British Society for Haematology (2018) · British Journal of Haematology · doi:10.1111/bjh.15235 · Cited by 104
Metadata
- Authors
- Fitzhugh, C. D., Hsieh, M. M., Allen, D., Coles, W. A., Seamon, C., Ring, M., Zhao, X., Minniti, C. P., Rodgers, G. P., Schechter, A. N., Tisdale, J. F., & Taylor, J. G.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Taylor, James G.
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-11-17
- Volume
- 10
- Issue
- 11
- Pages
- e0141706
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4648496
- OpenAlex
- W2174941367
- Semantic Scholar
- 80467cdbafaf1aba24e6bceb076ceb4177a49c7c
- Cited by
- 64
- References
- 31
- Citations by year
- 2026: 6 · 2025: 4 · 2024: 5 · 2023: 5 · 2022: 9 · 2021: 2 · 2020: 4 · 2019: 10 · 2018: 6 · 2017: 10 · 2016: 3
- FWCI
- 3.54
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- public-domain
- creativecommons.org/publicdomain/zero/1.0/ (vor)
- Locations
- PLoS ONE (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion, public-domain)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute (ZIAHL006012)
- National Institute of Diabetes and Digestive and Kidney Diseases
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Hematology › Blood groups and transfusion
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Hemoglobin structure and function
- Keywords
- hydroxyurea, sickle cell disease, fetal hemoglobin, organ damage, survival, liver dysfunction, renal dysfunction, cardiopulmonary dysfunction, alkaline phosphatase, creatinine, adults with sickle cell disease, hydroxyurea resistance, hydroxyurea intolerance
- MeSH terms
- Adolescent, Adult, Aged, Anemia, Sickle Cell, Antisickling Agents, Female, Fetal Hemoglobin, Humans, Hydroxyurea, Male, Middle Aged, Retrospective Studies, Proportional Hazards Models, Treatment Outcome, Maximum Tolerated Dose, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.